When GlaxoSmithKline made a clean sweep of Human Genome Sciences execs last year following its $3.6 billion buyout of the Rockville biotech, one big question (among many) was where would they land?
At least two have found their way back into Maryland biotechs. Last month, former HGS chief commercial officer Barry Labinger joined Anthrax-vaccine-maker Emergent BioSolutions as head of its bioscience division. And on Thursday, pre-IPO biotech MacroGenics announced the appointment of David Stump, formerly executive vice president for research and development at Human Genome, to its board of directors.